Full Text View
Tabular View
Study Results
Related Studies
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
This study has been completed.
Study NCT00782184   Information provided by Merck Sharp & Dohme Corp.

First Received on October 29, 2008.   Last Updated on October 24, 2014   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial